AR065795A1 - Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros. - Google Patents

Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.

Info

Publication number
AR065795A1
AR065795A1 ARP080101143A ARP080101143A AR065795A1 AR 065795 A1 AR065795 A1 AR 065795A1 AR P080101143 A ARP080101143 A AR P080101143A AR P080101143 A ARP080101143 A AR P080101143A AR 065795 A1 AR065795 A1 AR 065795A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
fluor
alkyl
alkoxy
cycloalkyl
Prior art date
Application number
ARP080101143A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39473201&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065795(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR065795A1 publication Critical patent/AR065795A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Abstract

Estos compuestos son agonistas del HM74A y pueden emplearse como medicamentos. Reivindicacion 1: Compuestos de formula (1) en donde X1 es N o C(R6); X2 es N o C(R7); X3 es N o C(R8), en donde por lo menos uno de X1, X2 y X3 es N; Y es un enlacesencillo, O, N(R9)C(O), C(O)NR9, N(R9)C(O)O, OC(O)NR9, N(R9)C(O)NR10, N(R9)SO2 o SO2N(R9); Z es un enlace sencillo, o, si n es 1, 2, 3, 4, 5 o 6, Y puede también ser O; R1, R2, R3 y R4 independientemente entre si son hidrogeno, fluor, alquiloinferior o fluor-alquilo inferior, o R1 y R2 están unidos juntamente para formar un anillo juntamente con el átomo de carbono al cual están unidos y -R1-R2- es -(CH2)2-6-, o R3 y R4 están unidos juntamente para formar un anillo juntamente con elátomo de carbono al cual están unidos, y -R3-R4- es -(CH2)2-6-; R5 es arilo o heteroarilo, el cual arilo o heteroarilo está opcionalmente substituido con 1 a 3 sustituyentes independientemente seleccionados del grupo formado por halogeno, alquiloinferior, alcoxilo inferior, fluor-alquilo inferior, fluor-alcoxilo inferior, cicloalquilo, fluor-cicloalquilo, cicloalquil-oxilo, C(O)OH, alcoxilo inferior-C(O), NH2C(O), N(H,alquilo inferior)C(O), N(alquilo inferior)2C(O), OH, alquilo inferior-C(O)O, NH2, N(H, alquilo inferior), N(alquilo inferior)2, alquilo inferior-C(O)NH, alquilo inferior-C(O)N(alquilo inferior), NH2SO2, N(H, alquilo inferior)SO2, N(alquilo inferior)2SO2, alquilo inferior-SO2-NH, alquilo inferior-SO2-N(alquiloinferior), ciano y fenilo el cual está opcionalmente substituido con 1 a 3 substituyentes independientemente seleccionados del grupo formado por halogeno, alquilo inferior, alcoxilo inferior y fluor-alquilo inferior; R6 es hidrogeno, halogeno,alquilo inferior, fluor-alquilo inferior, alcoxilo inferior, fluor-alcoxilo inferior o cicloalquilo; R7 es hidrogeno, halogeno, alquilo inferior, fluor-alquilo inferior, alcoxilo inferior, fluor-alcoxilo inferior o cicloalquilo; R8 es hidrogeno,halogeno, alquilo inferior, fluor-alquilo inferior, alcoxilo inferior, fluor-alcoxilo inferior o cicloalquilo; R9 y R10 independientemente entre sí son hidrogeno, alquilo inferior o fluor-alquilo inferior; m es 0, 1, 2 o 3; n es 0, 1, 2, 3, 4, 5 o6; en donde m + n es >=1; con la condicion de que si X1 es CH, X2 es CH y X3 es N, m + n no es 1; y las sales y ésteres farmacéuticamente aceptables de los mismos.
ARP080101143A 2007-03-23 2008-03-19 Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros. AR065795A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07104801 2007-03-23

Publications (1)

Publication Number Publication Date
AR065795A1 true AR065795A1 (es) 2009-07-01

Family

ID=39473201

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101143A AR065795A1 (es) 2007-03-23 2008-03-19 Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.

Country Status (15)

Country Link
US (1) US7928106B2 (es)
EP (1) EP2139895A1 (es)
JP (1) JP2010521513A (es)
KR (1) KR101115891B1 (es)
CN (1) CN101641358A (es)
AR (1) AR065795A1 (es)
AU (1) AU2008231873B2 (es)
BR (1) BRPI0808721A2 (es)
CA (1) CA2680775A1 (es)
CL (1) CL2008000806A1 (es)
IL (1) IL200618A0 (es)
MX (1) MX2009010218A (es)
PE (1) PE20090189A1 (es)
TW (1) TW200902532A (es)
WO (1) WO2008116742A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2010127208A1 (en) * 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
CN105616420A (zh) * 2016-01-16 2016-06-01 赵国良 一种降血脂的药物组合物
CN105853737A (zh) * 2016-05-17 2016-08-17 范信 一种治疗风湿、颈肩腰腿痛的药物
ES2944306T3 (es) 2017-12-21 2023-06-20 Boehringer Ingelheim Int Piridopirimidinonas sustituidas por bencilamino y derivados como inhibidores de SOS1
CN108218861B (zh) * 2018-02-05 2019-07-23 黑龙江中医药大学 一种预防和治疗糖尿病的药物及其制备方法
CN115605462A (zh) 2020-05-12 2023-01-13 拜耳公司（De） 作为杀真菌化合物的三嗪和嘧啶(硫代)酰胺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2378912A1 (fr) 1977-01-26 1978-08-25 Pollet Sa Cloison amovible ou demontable et elements constitutifs de ladite cloison
FR2645152B1 (fr) * 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
KR101100601B1 (ko) * 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 신규 화합물
KR20070008709A (ko) * 2004-04-30 2007-01-17 다케다 야쿠힌 고교 가부시키가이샤 이종환식 아미드 화합물 및 이의 ｍｍｐ-13 저해제로서의용도
WO2006023381A1 (en) * 2004-08-16 2006-03-02 Taigen Biotechnology Pyrimidinone compounds
ITBO20050076A1 (it) 2005-02-17 2006-08-18 Metal Work Srl Struttura per il supporto di elementi a definire una parete
AU2006247695B2 (en) * 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
JP5112423B2 (ja) 2006-05-23 2013-01-09 エフ．ホフマン−ラ ロシュ アーゲー ピリドピリミジノン誘導体

Also Published As

Publication number Publication date
US7928106B2 (en) 2011-04-19
CN101641358A (zh) 2010-02-03
WO2008116742A1 (en) 2008-10-02
BRPI0808721A2 (pt) 2014-08-12
EP2139895A1 (en) 2010-01-06
MX2009010218A (es) 2009-10-19
KR20090122964A (ko) 2009-12-01
TW200902532A (en) 2009-01-16
AU2008231873B2 (en) 2011-11-10
US20080234277A1 (en) 2008-09-25
CA2680775A1 (en) 2008-10-02
PE20090189A1 (es) 2009-03-12
JP2010521513A (ja) 2010-06-24
KR101115891B1 (ko) 2012-02-13
CL2008000806A1 (es) 2008-11-07
AU2008231873A1 (en) 2008-10-02
IL200618A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
AR070437A1 (es) Moduladores de beta - amiloide
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
AR056265A1 (es) N-aminometilensulfonamidas sustituidas, su preparacion y su uso como medicamentos
PE20060620A1 (es) Analogos de biaril piperazinil-piridina sustituidos como moduladores del receptor de capsaicina vr1
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
AR069814A1 (es) Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen
AR069480A1 (es) Derivados de 2-amino-pirimidina
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
PE20140968A1 (es) Derivados de benzamida sustituida
AR051325A1 (es) Analogos de biarilquinolin-4-ilamina sustituidos
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR075531A1 (es) Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros
CO5601021A2 (es) Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb
AR052308A1 (es) Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
AR119843A1 (es) Derivados de estrigolactonas como reguladores del crecimiento vegetal

Legal Events

Date Code Title Description
FA Abandonment or withdrawal